2018 Communication Drug Development 
pharmaphorum
AUGUST 26, 2021
There are many benefits of including patients at every stage of the drug development process, as well as ways to involve them in the early stages of drug development. It helps to focus the drug development process on its main element – the patient, and it also makes good business sense, too.
pharmaphorum
APRIL 19, 2021
Prime Global, the international medical communications and market access group, has appointed Emma Sutcliffe as senior vice president, patient insights and solutions. Sutcliffe will lead on patient engagement and support Prime Global’s seven agencies and four consultancies to deliver patient-centric communications.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 6, 2022
HPAPIs may now represent more than 30% of the drug development pipeline. Within that figure, GlobalData estimates that around 60% of pipeline HPAPIs are developed to target oncology. Between 2018 and 2020, 58% of the small molecule API contract manufacturing sites purchased worldwide offered containment.
Pharmaceutical Technology
JANUARY 22, 2023
In 2022, the FDA approved only 37 new medicines, an underwhelming number compared to 98 in 2018. However, while only around 34% of the approvals in 2018 were for orphan drugs, 54% new approvals in 2022 were for drugs to treat rare diseases. compared to 38.5% on placebo. Please check your email to download the Report.
Pharmaceutical Technology
APRIL 26, 2023
First approved in 2018, the system has since been used across different settings for asthmatic patients. Devices can also improve patient-provider communication and patient self-management by providing more detailed insights into their medication-taking and how it relates to their asthma control.
Pharmaceutical Technology
NOVEMBER 30, 2022
A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. The same can be said for the US. of adults were overweight, 42.4% were obese, and 9.2%
Pharmaceutical Technology
NOVEMBER 30, 2022
A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. The same can be said for the US. of adults were overweight, 42.4% were obese, and 9.2%
Expert insights. Personalized for you.
105 
Let's personalize your content